NCT01141595 - Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Autism Spectrum Disorder

Interventions

DRUG

sapropterin dihydrochloride

Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.

Trial Locations (1)

Arkansas Children's Hospital Research Institute, Little Rock